-

Zhangmen Education Inc. Shareholder Alert: Robbins LLP Informs Investors that Zhangmen Education Inc. (ZME) is Being Sued for Misleading Investors

SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP informs investors that a class action was filed on behalf of all persons and entities that purchased Zhangmen Education Inc. (NYSE: ZME) American Depository Shares ("ADSs") pursuant to the Company's June 2021 initial public offering ("IPO"). The complaint alleges violations of the Securities Act of 1933. Zhangmen is an education company focused on providing personalized online courses to K-12 students in China.

If you suffered a loss due to Zhangmen Education Inc.'s misconduct, click here.

Zhangmen Education Inc. (ZME) Misled Investors Regarding its Business Prospects

According to the complaint, Zhangmen filed its Prospectus, which forms part of the Registration Statement for the IPO, with the Securities & Exchange Commission, offering 3.623 million ADSs at $11.50 per ADS. However, defendants failed to disclose that prior to the IPO, China had adopted stringent new regulations aimed at curbing fraud in China's online education market. This sweeping crackdown on the Chinese tutoring industry would effectively ban profit-making in the sector, essentially destroying Zhangmen's business and prospects.

On July 23, 2021, China unveiled its overhaul of the education sector, banning companies that teach school curriculum from making profits, raising capital, or going public. Zhangmen's ADSs now trade at less than $1.50 per ADS.

If you purchased Zhangmen Education Inc. (ZME) ADSs pursuant to the Company's June 2021 IPO, you have until January 18, 2022, to ask the court to appoint you lead plaintiff for the class.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

Contact us to learn more:

Aaron Dumas
(800) 350-6003
adumas@robbinsllp.com
Shareholder Information Form

About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against Zhangmen Education Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Aaron Dumas
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

Investor Notice: Shareholder Rights Law Firm Robbins LLP Informs Investors of the uniQure N.V. Securities Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired uniQure N.V. (NASDAQ: QURE) ordinary shares between September 24, 2025 and October 31, 2025. uniQure is a biotechnology company developing gene therapies for rare diseases. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating Allegations that un...

Investor Notice: Shareholder Rights Law Firm Robbins LLP Informs Investors of the POMDoctor Ltd. Securities Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired POMDoctor, Ltd. (NASDAQ: POM) securities between October 9, 2025 and December 11, 2025. POMDoctor claims to be "a leading online medical services platform for chronic diseases in China." For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating Alleg...

Investor Notice: Shareholder Rights Law Firm Robbins LLP Informs Investors of the Inovio Pharmaceuticals, Inc. Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all persons that purchased or otherwise acquired Inovio Pharmaceuticals, Inc. (NASDAQ: INO) securities between October 10, 2023 and December 26, 2025. Inovio is a biotechnology company focused on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with, inter alia, human papillomavirus (“HPV”). For more information, submit a...
Back to Newsroom